Navigation Links
ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin,Conjugate Data Presented at American Diabetes Association Annual,Meeting

MONTREAL, June 19 /CNW/ - ConjuChem Biotechnologies (TSX:CJB) today announced that data relating to its proprietary PC-DAC(TM):Exendin-4 Albumin Conjugate for the treatment of Type 2 diabetes will be presented at the 67th Scientific Sessions of the American Diabetes Association (ADA) to be held June 22-26, 2007 in Chicago, IL. The ADA's annual Scientific Sessions meeting is one of the largest gatherings of health care professionals involved in diabetes research and the delivery of diabetes care.

"These encouraging results from our Phase I/II multiple-dose clinical studies demonstrate that our PC-DAC(TM):Exendin-4 Albumin Conjugate is a well-tolerated and effective therapy," said Mark D. Perrin, President and CEO. "The data was further evidence of our compound's potential to become a once-weekly treatment for Type 2 diabetes."

The study titled "PC-DAC(TM):Exendin-4 (CJC-1134-PC) Demonstrates Safety and Efficacy as an Adjunct Therapy to Metformin: A Randomized, Double-Blind, Placebo-Controlled, One Month Phase I/II Study in 70 Patients with Type 2 Diabetes Mellitus", authored by Maggie Wang et al., was featured as a late breaking abstract. Seventy patients were enrolled in US and Canada and randomized to 1 mg, 2mg, 3mg of PC-DAC(TM):Exendin-4 or placebo treatment groups. All three treatment groups experienced reductions in fasting plasma glucose that were statistically significant versus baseline (p less than 0.005) and versus placebo (p less than 0.03) over the 5-week treatment period. Median HbA1c values decreased from baseline by 0.7%, 0.8% and 0.9% in the 1mg, 2mg, and 3mg groups, respectively, at the end of the study (Day 63) and were statistically significant (p less than 0.03 by ANCOVA) between pooled active patients (n=52) and placebo (n=18). There was no significant change in weight in the treatment cohorts (baseline 81-85kg) at the end of the treatment period. Generally low-titer antibodies were de
'"/>




Page: 1 2 3

Related medicine technology :

1. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
2. Gemin X Biotechnologies Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:12/24/2014)... CHENGDU, China, Dec. 24, 2014 /PRNewswire/  -- Tianyin ... a pharmaceutical company that specializes in the patented ... and active pharmaceutical ingredients (API) released unaudited preliminary ... year 2015. Fiscal Year 2015 Ended ... was $9.7 million compared with $14.7 million in ...
(Date:12/24/2014)... 24, 2014  Diplomat Pharmacy, Inc. (NYSE: ... proud to announce Jennifer Hagerman , Pharm.D., AE-C, ... take office as the president of the Michigan Pharmacists ... will take place Feb. 28, 2015, at the MPA ... the Renaissance Center in Detroit, Michigan ...
(Date:12/24/2014)... 23, 2014  Advanced Medical Isotope Corporation ("AMIC") ... in the development of brachytherapy devices and medical ... that it has filed a de novo ... ("FDA") for marketing clearance for its patented Y-90 ... U.S. Food, Drug and Cosmetic Act (the "Act").  ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... Inc. (Nasdaq: CRTX ) today announced that it ... Thursday, November 4, 2010, to discuss its financial results for ... results are expected to be released on Thursday, November 4, ... in the live conference call, please dial 866-804-6927 (U.S. callers) ...
... See video from AstraZeneca at: ... Anglo-Swedish pharmaceutical company AstraZeneca announced that revenue ... at constant exchange rates (CER) to $7,898 ... for Crestor, Symbicort and Seroquel XR. Revenue ...
Cached Medicine Technology:Cornerstone Therapeutics to Host Third Quarter 2010 Conference Call 2Cornerstone Therapeutics to Host Third Quarter 2010 Conference Call 3
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a comprehensive high-tech ... marketing of a series of induction heating equipment. Today, ... of induction brazing equipments . , According to ... refers to the joining of two or more ... manager says that there are fundamental differences in the ...
(Date:12/25/2014)... The microscopy market is estimated to grow ... million by 2019. Optical microscopy is the largest ... product segment is expected to show the fastest ... on nanotechnology, technological advancements, and increasing federal support ... Get Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
(Date:12/25/2014)... The click strand woven bamboo flooring ... Today, the business announces a click strand woven ... 30, 2015. , Click strand woven bamboo flooring ... a well-known brand in the bamboo industry. It ... reliable bamboo flooring supplier. , “We are happy ...
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – ... current treatment landscape, unmet needs, current pipeline and commercial ... anti-cancer drug which is typically used for treating colorectal ... for treating gastric cancer and pancreatic cancer. TS-1 is ... was first approved in 1999 in Japan for the ...
(Date:12/25/2014)... “Every three months the trends for ... evening dress will be one of the hottest styles in ... says. Today, the company releases 26 A-line sweetheart evening dresses, ... off. , “We are trying our best to help ... latest designs. Along with affordable prices, we provide discounted delivery ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... People undergoing bisphosphonate therapy to prevent or treat osteoporosis ... drug and possible adverse side effects on oral health, according ... Journal of the American Dental Association (JADA). , Use ... developing bisphosphonate-associated osteonecrosis of the jaw (BON) that occurs spontaneously ...
... ... Respect™ Medical Center in the Anti-Defamation League’s (ADL’s) Southwest Region. , ... Houston, TX (Vocus) ... of Respect™ Medical Center in the Anti-Defamation League’s (ADL’s) Southwest Region. The Community ...
... ... one option for addressing health reform’s new medication waste reduction mandates , ... Phoenix, AZ (PRWEB) May 26, ... its world-class software and proven hardware components to enhance efficiency, provide greater inventory control, ...
... ... to $100,000 per-violation penalties , ... Alexandria, VA (Vocus) May 26, 2010 -- More than ten major retailers, ... (CEN) offered by the National Association of Chain Drug Stores (NACDS) and RollStream. ...
... is female sterilization, study shows , WEDNESDAY, May 26 (HealthDay ... after it was invented, the oral contraceptive remains the leading ... report says, just edging out female sterilization. , Interviews ... aged 15-44 were using the birth-control pill, while 10.3 million ...
... July 2010, Stockholm, Sweden, Stockholm International Fair and Congress ... a major risk factor for several chronic diseases, including ... of the leading preventable causes of death worldwide. The ... health challenges of the 21st century. The ...
Cached Medicine News:Health News:Some bisphosphonates users unfamiliar with drug's possible side effects on oral health 2Health News:Houston Northwest Medical Center Becomes First Hospital in the Southwest Region Designated a Community of Respect™ Partner 2Health News:Talyst Reaches Major Milestone: 500 Implementations in Long-Term Care, Acute Care and Corrections 2Health News:Talyst Reaches Major Milestone: 500 Implementations in Long-Term Care, Acute Care and Corrections 3Health News:Retailers and Manufacturers Quickly Adopt Online Network to Address CPSIA Compliance 2Health News:Retailers and Manufacturers Quickly Adopt Online Network to Address CPSIA Compliance 3Health News:Media arrangements for the International Congress on Obesity 2
... to adults, the entire series of time-tested ... of the needs of care providers and ... the accuracy. You can see it in ... the performance, year after year. Every Timeter® ...
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
Medicine Products: